NYBCe Expands MSC Manufacturing Partnership With Human Life CORD

February 28, 2025

New York Blood Center Enterprises (NYBCe), an AABB institutional member, and Human Life CORD Japan Inc. signed a letter of intent Feb. 27 to expand their manufacturing collaboration for umbilical cord-derived mesenchymal stromal cells (MSCs) through NYBCe’s Comprehensive Cell Solutions. The partnership aims to harmonize Human Life CORD’s MSC manufacturing platform internationally and strengthen its presence in North America.

Leaders from both organizations highlighted the collaboration’s potential to drive innovation, improve access to MSC-based therapies and enhance standardization in manufacturing.

“We are excited to partner with CCS of NYBCe to expand the manufacturing capabilities of umbilical cord-derived MSCs to a global standard,” said Masamitsu Harata, representative director, president and CEO of Human Life CORD. “By combining expertise from Japan and the U.S., we aim to establish a highly reproducible and scalable platform, making advanced cell therapy more accessible worldwide.”